DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD
DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).
Previous Post
Gallbladder Removal With 3-Plus Risk Factors May Increase MASLD Risk
Next Post
Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago